12 ms·
Moderna, Merck Vaccine Succeeds in Preventing Melanoma from Returning
- cebert 1mo agoGift link: https://www.wsj.com/health/pharma/moderna-merck-vaccine-succeeds-in-preventing-melanoma-from-returning-540e9e18?st=5uKZjA&reflink=desktopwebshare_permalink https://www.wsj.com/health/pharma/moderna-merck-vaccine-succ...
- rvz 1mo agoThe news here is significant and this took decades of studies and research to validate this. Well done to Merck and Moderna.
- deleted 1mo ago[deleted]
- deleted 1mo ago[deleted]
- deleted 1mo ago[deleted]
- johnbarron 1mo ago[dead]
- root-parent 1mo agoThere is nothing to see here yet other than their stock popped 50%. Based on unpublished data... - The initial 49% number comes from a very small phase 2 trial that had only 157 patients. And their original p-value was 0.053 - This phase 3 news so far is nothing more than a press release. They have not published hazard ratio, or confidence interval, their event counts or survival curves. - They met the endppoint as used in the press release means nothing, until they publish the actual 3 data, so my money is at the end this will be a kind of marginal effect that researchers will struggle to reproduce for years This is the type of study that will take 3 to 4 years to validate or dismiss, in the meanwhile stock is up 50%....